Corvex, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Corvex, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $433.0K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $1.01M | Mar 31, 2026 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($18.29M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($23.73M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($29.28M) | Apr 9, 2025 |
| FY2023 | Dec 31, 2022 | ($30.33M) | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | ($21.77M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($13.03M) | Mar 30, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($15.50M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($24.22M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($29.69M) | Apr 9, 2025 |
| FY2023 | Dec 31, 2022 | ($30.46M) | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | ($19.80M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($11.11M) | Mar 30, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.74M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $11.20M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $16.89M | Apr 9, 2025 |
| FY2023 | Dec 31, 2022 | $18.99M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $13.43M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $8.37M | Mar 30, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($11.27M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($22.53M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($26.18M) | Apr 9, 2025 |
| FY2023 | Dec 31, 2022 | ($24.90M) | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | ($16.18M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($10.67M) | Mar 30, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2024 | $8.0K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $64.0K | Apr 9, 2025 |
| FY2023 | Dec 31, 2022 | $105.0K | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $565.0K | Mar 30, 2023 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.60M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $11.32M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $9.42M | Apr 9, 2025 |
| FY2023 | Dec 31, 2022 | $13.24M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $36.27M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $7.08M | Mar 30, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.07M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $3.97M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $5.97M | Apr 9, 2025 |
| FY2023 | Dec 31, 2022 | $5.33M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $3.54M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $15.15M | Mar 30, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($3.47M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $7.36M | Mar 31, 2026 |
| FY2025 | Dec 31, 2023 | $3.45M | Mar 31, 2026 |
| FY2024 | Dec 31, 2022 | $7.92M | Apr 9, 2025 |
| FY2023 | Dec 31, 2021 | $32.73M | Apr 16, 2024 |
| FY2022 | Dec 31, 2020 | ($40.88M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2019 | ($19.91M) | Mar 30, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($166.39M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($148.11M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($124.38M) | Apr 9, 2025 |
| FY2023 | Dec 31, 2022 | ($95.10M) | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | ($64.77M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($40.88M) | Mar 30, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.83M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $7.90M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $6.12M | Apr 9, 2025 |
| FY2023 | Dec 31, 2022 | $10.76M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $17.68M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $5.71M | Mar 30, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (21) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | (39) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | (9) | Apr 9, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 30, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (21) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | (39) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | (9) | Apr 9, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 30, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 904,486 | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 684,029 | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 3.72M | Apr 9, 2025 |
| FY2023 | Dec 31, 2022 | 33.66M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | 32.77M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | 6.39M | Mar 30, 2022 |